Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vivos Therapeutics (VVOS) Revenue (2020 - 2025)

Vivos Therapeutics has reported Revenue over the past 6 years, most recently at $3.8 million for Q4 2025.

  • Quarterly Revenue rose 3.41% to $3.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $17.4 million through Dec 2025, up 16.05% year-over-year, with the annual reading at $17.4 million for FY2025, 16.05% up from the prior year.
  • Revenue was $3.8 million for Q4 2025 at Vivos Therapeutics, down from $6.8 million in the prior quarter.
  • Over five years, Revenue peaked at $6.8 million in Q3 2025 and troughed at $3.0 million in Q1 2025.
  • The 5-year median for Revenue is $3.8 million (2023), against an average of $4.0 million.
  • Year-over-year, Revenue dropped 22.26% in 2023 and then surged 75.73% in 2025.
  • A 5-year view of Revenue shows it stood at $4.4 million in 2021, then fell by 10.1% to $4.0 million in 2022, then fell by 17.77% to $3.2 million in 2023, then increased by 13.85% to $3.7 million in 2024, then grew by 3.41% to $3.8 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Revenue are $3.8 million (Q4 2025), $6.8 million (Q3 2025), and $3.8 million (Q2 2025).